ArticlePharmaceuticals (Basel, Switzerland)2023
Dihydromyricetin Modulates Nrf2 and NF-κB Crosstalk to Alleviate Methotrexate-Induced Lung Toxicity.
Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 20 citations in OpenAlex.
- Current perspectives on natural and pharmacological interventions for combating drug-induced pulmonary toxicity.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Therapeutic effects of Rosmarinus officinalis against methotrexate-induced submandibular salivary gland injury in male albino rats.Journal of molecular histology · 2026Article
- Rosemary (Rosmarinus officinalis) Extract Attenuates Methotrexate-Induced Oxidative Stress, Inflammatory Disturbance, and Apoptotic Lung Injury: A Molecular and Histopathological Study.Cell biochemistry and biophysics · 2026Article
- Agomelatine Alleviates Methotrexate-Induced Lung Injury by Concurrently Inhibiting CD45/CD68-Positive Immune Cell Infiltration and Modulating the BAX/BCL2 Apoptosis Pathway.Journal of applied toxicology : JAT · 2026Article
- Celastrol alleviates synovial inflammation and joint destruction in rheumatoid arthritis in association with Nrf2/HO-1/GPX4 pathway activation.Molecular and cellular biochemistry · 2026Article
- Mechanistic Insights into Dihydromyricetin: Redox Modulation and Kinase-Mediated Control of Disease Pathogenesis.International journal of molecular sciences · 2026Review
- Nanocarrier-Based Therapeutic Strategies in Myocardial Ischemia-Reperfusion Injury: A Systematic Review of Preclinical Evidence.Biomedicines · 2026Review
- Mechanistic insights into the anti-benign prostatic hyperplasia effect of dihydromyricetin via suppression of the 5-AR/TGF-β1/Smad2 axis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ameliorative Role of Silymarin in Methotrexate-Induced Pulmonary Damage: A Multi-Pathway Molecular Approach.Journal of biochemical and molecular toxicology · 2026Article
- Morin hydrate alleviated cisplatin-induced testicular toxicity in rats via modulating NLRP3/NF-κB pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- Exploring the beneficial effects of curcumin-based hydrogel beads in rats with rheumatoid arthritis induced by Freund's complete adjuvant.Molecular and cellular biochemistry · 2026Article
- Article
- Preclinical research of dihydromyricetin for fibrotic diseases.Frontiers in pharmacology · 2025Review
- Modified citrus pectin ameliorates methotrexate-induced hepatic and pulmonary toxicity: role of Nrf2, galectin-3/TLR-4/NF-κB/TNF-α and TGF-β signaling pathways.Frontiers in pharmacology · 2025Article
- Dihydromyricetin Inhibits Ferroptosis to Attenuate Cisplatin-Induced Muscle Atrophy.Physiological research · 2024Article
- Protective effect and pharmacokinetics of dihydromyricetin nanoparticles on oxidative damage of myocardium.PloS one · 2024Article
- Dihydromyricetin: an emerging compound with comprehensive effects on multiple systems.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethotrexate (MTX) is an effective anticancer, anti-inflammatory, and immunomodulatory agent. However, it induces a serious pneumonitis that leads to irreversible fibrotic lung damage. This study addresses the protective role of the natural flavonoid dihydromyricetin (DHM) against MTX-induced pneumonitis via modulation of Nrf2/NF-κB signaling crosstalk.
methodsMale Wistar rats were divided into 4 groups: control, which received the vehicle; MTX, which received a single MTX (40 mg/kg, i.p) at day 9 of the experiment; (MTX + DHM), which received oral DHM (300 mg/kg) for 14 days and methotrexate (40 mg/kg, i.p) on the 9th day; and DHM, which received DHM (300 mg/kg, p.o) for 14 days.
resultsLung histopathological examination and scoring showed a decline in MTX-induced alveolar epithelial damage and decreased inflammatory cell infiltration by DHM treatment. Further, DHM significantly alleviated the oxidative stress by decreasing MDA while increasing GSH and SOD antioxidant levels. Additionally, DHM suppressed the pulmonary inflammation and fibrosis through decreasing levels of NF-κB, IL-1β, and TGF-β1 while promoting the expression of Nrf2, a positive regulator of antioxidant genes, and its downstream modulator, HO-1.
conclusionThis study identified DHM as a promising therapeutic target against MTX-induced pneumonitis via activation of Nrf2 antioxidant signaling while suppressing the NF-κB mediated inflammatory pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.